Updated on 6 March 2015
DKSH Business Unit Healthcare, a Zurich-based marketing partner for healthcare companies, will provide marketing, sales and regulatory services as well as distribution and logistics for Sumitomo Dainippon Pharma's Lurasidone Hydrochloride (Lurasidone) in Thailand, Singapore and Hong Kong.
Lurasidone is a prescription drug in tablet form first approved in the US for the treatment of adult patients with schizophrenia and bipolar disorder. The sales and distribution of lurasidone is pending the drug's approval by the health authorities of Thailand, Singapore and Hong Kong. Once approved, the agreement will further strengthen DKSH's market position in the region.
Lurasidone is an atypical antipsychotic developed originally by Sumitomo Dainippon Pharma, characterized by a unique chemical structure and an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects. In addition, lurasidone is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine or muscarinic receptors.
Under the brand name of Latuda, lurasidone has been available for the treatment of adults with schizophrenia in the United States since February 2011, in Canada since September 2012, in Switzerland since September 2013, in the U.K. since August 2014 and in Norway since September 2014.
Sumitomo Dainippon Pharma is conducting Phase III clinical trials with a view to acquiring approval of lurasidone for the treatment of schizophrenia in Japan and mainland China. Similar efforts are ongoing in collaboration with Takeda Pharmaceutical Company Limited for 30 European and other countries, with Daiichi Sankyo Company, Limited for four Latin American countries and with Standard Chem. & Pharm. Co., Ltd. For the Taiwan region.